Chronic Kidney Disease Prevalence and Rate of Diagnosis

Similar documents
Chronic kidney disease (CKD) has received

From Department of Medicine, David Geffen School of Medicine at UCLA.

TREAT THE KIDNEY TO SAVE THE HEART. Leanna Tyshler, MD Chronic Kidney Disease Medical Advisor Northwest Kidney Centers February 2 nd, 2009

Is the new Mayo Clinic Quadratic (MCQ) equation useful for the estimation of glomerular filtration rate in type 2 diabetic patients?

Chapter 2: Identification and Care of Patients With CKD

USRDS UNITED STATES RENAL DATA SYSTEM

Chronic Kidney Disease

Defining risk factors associated with renal and cognitive dysfunction Joosten, Johanna Maria Helena

Figure 1 LVH: Allowed Cost by Claim Volume (Data generated from a Populytics analysis).

Long-term outcomes in nondiabetic chronic kidney disease

Acknowledgements. National Kidney Foundation of Connecticut Mark Perazella. Co-PI Slowing the progression of chronic kidney disease to ESRD

Two: Chronic kidney disease identified in the claims data. Chapter

Classification of CKD by Diagnosis

Letter to the Editor SPECIAL COMMUNICATION

Concept and General Objectives of the Conference: Prognosis Matters. Andrew S. Levey, MD Tufts Medical Center Boston, MA

Chapter 2: Identification and Care of Patients With CKD

Chronic Kidney Disease: Optimal and Coordinated Management

Screening and early recognition of CKD. John Ngigi (FISN) Kidney specialist

Masatoshi Kawashima 1, Koji Wada 2, Hiroshi Ohta 2, Rika Moriya 3 and Yoshiharu Aizawa 1. Journal of Occupational Health

Chapter 2: Identification and Care of Patients with CKD

THE PROGNOSIS OF PATIENTS WITH CHRONIC KIDNEY DISEASE AND DIABETES MELLITUS

Analytical Methods: the Kidney Early Evaluation Program (KEEP) The Kidney Early Evaluation program (KEEP) is a free, community based health

High Prevalence of Stage 3 Chronic Kidney Disease in Older Adults Despite Normal Serum Creatinine

Agroup of clinicians, researchers, ... REPORT... Chronic Kidney Disease: Stating the Managed Care Case for Early Treatment

Chapter 2: Identification and Care of Patients With Chronic Kidney Disease

Outline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?

Elevation of Serum Creatinine: When to Screen, When to Refer. Bruce F. Culleton, MD, FRCPC; and Jolanta Karpinski, MD, FRCPC

ISPUB.COM. J Reed III, N Kopyt INTRODUCTION METHODS AND MATERIALS

THE ADVANCED CHRONIC KIDNEY DISEASE MANAGEMENT TOOLKIT

Outline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 7/23/2013. Question 1: Which of these patients has CKD?

Chronic Kidney Disease is Associated with Cognitive Decline: the Northern Manhattan Study (NOMAS) Seattle VA Chief of Medicine Rounds June 9, 2009

Assessment of glomerular filtration rate in healthy subjects and normoalbuminuric diabetic patients: validity of a new (MDRD) prediction equation

An epidemic of chronic kidney disease: fact or fiction?

Elevated relative mortality risk with mild-to-moderate chronic kidney disease decreases with age

A n aly tical m e t h o d s

Outline. Outline 10/14/2014 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?

Can modifications of the MDRD formula improve the estimation of glomerular filtration rate in renal allograft recipients?

KEEP 2.0 Annual Data Report Chapter Five

Are prediction equations for glomerular filtration rate useful for the long-term monitoring of type 2 diabetic patients?

ORIGINAL INVESTIGATION. Serum Creatinine Is an Inadequate Screening Test for Renal Failure in Elderly Patients

Guest Speaker Evaluations Viewer Call-In Thanks to our Sponsors: Phone: Fax: Public Health Live T 2 B 2

Objectives. Pre-dialysis CKD: The Problem. Pre-dialysis CKD: The Problem. Objectives

Special Challenges and Co-Morbidities

The estimation of kidney function with different formulas in overall population

INDEX WORDS: Awareness; chronic kidney disease; Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI); estimated glomerular filtration rate.

S150 KEEP Analytical Methods. American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153

ALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR)

Zhao Y Y et al. Ann Intern Med 2012;156:

The incidence and prevalence of hypertension

Timely Referral to Outpatient Nephrology Care Slows Progression and Reduces Treatment Costs of Chronic Kidney Diseases

Department of Clinical Pathology, Faculty of Medicine Padjadjaran University-Dr. Hasan Sadikin General Hospital 2

Implications of the CKD-EPI GFR Estimation Equation in Clinical Practice

Screening for chronic kidney disease racial implications. Not everybody that pees has healthy kidneys!

Is There a Chronic Kidney Disease Epidemic? Profile of Chronic Kidney Disease in an Urban Renal Camp in Southern India

CHRONIC KIDNEY DISEASE

Recently, the National Kidney Foundation endorsed a

MANAGERIAL. Potential Application of the National Kidney Foundation s Chronic Kidney Disease Guidelines in a Managed Care Setting

CKD and risk management : NICE guideline

Disclosures. Outline. Outline 5/23/17 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW

Management of Early Kidney Disease: What to do Before Referring to the Nephrologist

The CARI Guidelines Caring for Australians with Renal Impairment. 5. Classification of chronic kidney disease based on evaluation of kidney function

CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH

Disclosures. Outline. Outline 7/27/2017 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW

Transfusion Burden among Patients with Chronic Kidney Disease and Anemia

Performance of MDRD study and CKD-EPI equations for long-term follow-up of nondiabetic patients with chronic kidney disease

Norman Poh Andrew McGovern Simon de Lusignan SEPTEMBER 2014 TR-14-03

Risk for chronic kidney disease increases with obesity: Health Survey for England 2010

Narender Goel et al. Middletown Medical PC, Montefiore Medical Center & Albert Einstein College of Medicine, New York

EPIDEMIOLOGY OF ARRHYTHMIAS AND OUTCOMES IN CKD & DIALYSIS KDIGO. Wolfgang C. Winkelmayer, MD, ScD Baylor College of Medicine Houston, Texas


The relation between estimated glomerular filtration rate and proteinuria in Okayama Prefecture, Japan

Carboplatin Time to Drop the Curtain on the Dosing Debate

Validation of El-Minia Equation for Estimation of Glomerular Filtration Rate in Different Stages of Chronic Kidney Disease

Chapter 1: CKD in the General Population

Outline. Outline. Introduction CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 8/11/2011

Characteristics of factor x so that its clearance = GFR. Such factors that meet these criteria. Renal Tests. Renal Tests

ASSESSMENT OF A POINT-OF-CARE DEVICE FOR MEASURING CREATININE IN A COMMUNITY SCREENING PROGRAM FOR CHRONIC KIDNEY DISEASE

Update on HIV-Related Kidney Diseases. Agenda

CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW

KEEP S u m m a r y F i g u r e s. American Journal of Kidney Diseases, Vol 53, No 4, Suppl 4, 2009:pp S32 S44.

Lessons learned from AASK (African-American Study of Kidney Disease and Hypertension)

Acceptance onto Dialysis Guidelines

Measurement and Estimation of renal function. Professeur Pierre Delanaye Université de Liège CHU Sart Tilman BELGIQUE

Glomerular filtration rate estimated by cystatin C among different clinical presentations

Chapter IV. Patient Characteristics at the Start of ESRD: Data from the HCFA Medical Evidence Form

Diabetes Mellitus in CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition and Examination Survey (NHANES)

Case Studies: Renal and Urologic Impairments Workshop

Chapter 3: Morbidity and Mortality in Patients with CKD

The impact of albuminuria and cardiovascular risk factors on renal function Verhave, Jacoba Catharijne

Εκηίμηζη ηης μεθρικής λειηοσργίας Ε. Μωραλίδης

Creatinine levels among Mexican Americans, Puerto Ricans, and Cuban Americans in the Hispanic Health and Nutrition Examination Survey

DIABETES AND CHRONIC KIDNEY DISEASE

patient characteriuics Chapter Two introduction 58 increasing complexity of the patient population 60 epo use & anemia in the pre-esrd period 62

The U.S. Preventive Services Task Force (USPSTF) makes

Diabetes and renal disease: who does what?

Correspondence should be addressed to Maisarah Jalalonmuhali;

Reducing proteinuria

Outline. Introduction. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 6/26/2012

CKD in the United States: An Overview of the USRDS Annual Data Report, Volume 1

Higher levels of Urinary Albumin Excretion within the Normal Range Predict Faster Decline in Glomerular Filtration Rate in Diabetic Patients

Transcription:

The American Journal of Medicine (2007) 120, 981-986 CLINICAL RESEARCH STUDY Chronic Kidney Disease Prevalence and Rate of Diagnosis Timothy P. Ryan, PhD, a James A. Sloand, MD, b Paul C. Winters, MS, a James P. Corsetti, MD, PhD, c Susan G. Fisher, PhD a a Department of Community and Preventive Medicine, Division of Epidemiology, b Department of Medicine, Division of Nephrology, and c Department of Pathology and Laboratory Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY. ABSTRACT BACKGROUND: Chronic kidney disease is a major public health problem. However, no study to date has estimated the prevalence of chronic kidney disease based on the clinical guidelines established by the National Kidney Foundation and few studies have explored the rate of diagnoses by primary care providers. SUBJECTS AND METHODS: Cross-sectional study of ambulatory patients in Rochester, NY. The purpose of this study was to estimate the prevalence of chronic kidney disease and the rate of primary caregiver diagnosis in ambulatory patients with chronic kidney disease. RESULTS: Among the 24,492 outpatients that had at least 2 glomerular filtration rate estimates 3 months apart, 6895 had an estimated glomerular filtration rate 60 ml/min/1.73 m 2, indicating a 28.2% period prevalence of chronic kidney disease. The rate of clinical diagnosis among those with chronic kidney disease was 26.5% (95% confidence interval, 17.9 to 35.1), suggesting that 74% of patients with chronic kidney disease are undiagnosed. CONCLUSIONS: We demonstrate that the prevalence of chronic kidney disease is substantially higher in health-seeking individuals than in the general population. Moreover, we demonstrate that laboratory reporting of estimated glomerular filtration rate using the Modification of Diet in Renal Disease equation alone does not result in an optimal rate of clinical diagnosis. 2007 Elsevier Inc. All rights reserved. KEYWORDS: Chronic kidney disease; Diagnosis; Glomerular filtration rate; MDRD; Prevalence Epidemic increases in chronic kidney disease have prompted the National Institutes of Health to include chronic kidney disease as a focus area in the Healthy People 2010 initiative. The 2010 guidelines call for reductions in: the rate of new cases of end-stage renal disease, the mortality rate related to chronic kidney disease, and kidney failure due to diabetes. 1 Recent medical evidence suggests that proper management of chronic kidney disease in the early stages can prevent death from cardiovascular disease, delay the need for dialysis, and improve patient health at the onset of dialysis. 2-7 While incidence and prevalence rates of end-stage renal disease are known, analogous rates for earlier stages of chronic kidney disease are limited. Chronic kidney disease Requests for reprints should be addressed to Timothy P. Ryan, PhD, Box 644, 601 Elmwood Avenue, Department of Community and Preventive Medicine, Division of Epidemiology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642. E-mail address: Tim_ryan@urmc.rochester.edu is defined as a glomerular filtration rate (GFR) 60 ml/ min/1.73 m 2 of body surface area for 3 months. 2 According to the Third National Health and Nutrition Examination Survey (NHANES III) from 1988-1994, an estimated 8.3 million adults in the US have chronic kidney disease, indicating a prevalence of 4.7%. 8 However, kidney function is based on a single estimate of GFR, as are similar estimates from other studies. 9-13 Lack of epidemiological data on the scope of early-stage chronic kidney disease hinders the development and evaluation of early intervention programs that could reduce the burden of disease. Although early stages of chronic kidney disease are typically asymptomatic, detection can be achieved through laboratory testing. All clinical laboratories in Monroe County, New York have adopted the Modification of Diet in Renal Disease (MDRD) 4-variable equation to aid in estimating patients serum creatinine (S cr )-based GFR. The equation has proven most accurate in individuals with 0002-9343/$ -see front matter 2007 Elsevier Inc. All rights reserved. doi:10.1016/j.amjmed.2007.05.012

982 The American Journal of Medicine, Vol 120, No 11, November 2007 chronic kidney disease and been further validated by direct measurement in patients 70 years of age. 2,14-19 The MDRD equation potentially enables early detection of chronic kidney disease, thus providing primary care physicians with an opportunity to delay disease progression. Few studies have attempted to estimate the rate of diagnoses of chronic kidney disease by primary care physicians. However, these studies were limited in that diagnostic decisions were based on S cr values alone. 12,20 Two major objectives of this study were: estimation of the period prevalence of chronic kidney disease as defined by MDRD-estimated GFR 60 ml/min/1.73 m 2 3 months, and estimation of the rate of primary caregiver recognition/diagnosis of chronic kidney disease. METHODS AND MATERIALS CLINICAL SIGNIFICANCE Study Population The study was conducted in Monroe County, New York, which has a population of 735,177. 21 Monroe County demographics are similar to those of the US, with 51% of residents being female and 13% aged 65 years. Monroe County has a slightly higher percentage of African Americans (13.7%) compared with that in the US (12.3%), and the median age of residents is slightly older (39.1 years) than that of the US population (35.3 years). 21,22 The laboratory at Strong Health (University of Rochester) processes both inpatient and ambulatory specimens, comprising roughly one third of all tests done in Monroe County. The ambulatory specimens are collected from primary care offices throughout the County, which increases the likelihood of a representative sample. The overall study population included all individuals 18 years of age or older as of June 1, 2003 who had at least one laboratory-estimated GFR from Strong Health between June 1, 2003 and May 31, 2004. Given the potential for renal insult and instability, inpatient estimates were excluded from the study. Individuals with missing demographic information or personal identifiers were also excluded. The study was approved by the Institutional Review Board at the University of Rochester Medical Center in accordance with Health Insurance Portability and Accountability Act guidelines. Data Source The database utilized in this study was maintained by Clinical Laboratory Services at Strong Health. The database contained patient information that was submitted on the Prior prevalence, defining chronic kidney disease as a single estimated glomerular filtration rate 60, was overstated by approximately 27%. The predictive value (positive predictive value) of a single estimated glomerular filtration rate 60 ml/min/1.73 m 2 as indicative of chronic kidney disease appears to be approximately 73%. Laboratory reporting of estimated glomerular filtration rate using the Modification of Diet in Renal Disease equation alone does not result in an optimal rate of clinical diagnosis, with 74% of patients going undiagnosed. laboratory requisition and provided on the laboratory reports to the requesting physicians. The clinical laboratory of Strong Health measured S cr using an enzymatic method on Vitros 950 analyzers (Ortho Clinical Diagnostics, Rochester, New York). In order to address the issue of bias among the various creatinine assay methods regarding GFR estimation, 23 a correlation study of 40 patients was performed comparing S cr values using the Vitros 950 enzymatic method to an ADVIA 2400 blank-corrected Jaffe method (Bayer HealthCare, Tarrytown, New York). The ADVIA assay is traceable to a high-performance liquid chromatography reference method and, as per manufacturer, the re-expressed MDRD equation GFR 175 * S cr 1.154 * age 0.203 * 0.742 if female * 1.210 if African- American is used to calculate GFRs. 14,24 S cr is measured in mg/dl, age is measured in years. A scatter plot of assay results demonstrated excellent correlation between the methods (R-square 0.9978). Outcomes of Interest For the purpose of this study, 2 outcomes were considered. First, the period prevalence of chronic kidney disease in patients seeking ambulatory health care was estimated. Chronic kidney disease was defined, utilizing the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines, as MDRD estimated GFR value 60 ml/min/1.73 m 2 for 3 months. 2 Reduced kidney function to a level of GFR 60 ml/min/1.73 m 2 represents 50% or more loss in normal adult kidney function. 2 This level of kidney dysfunction for 3 months indicates a chronic loss rather than acute reduction. The period prevalence was determined as the ratio of the number of patients with a GFR 60 ml/min/1.73 m 2 for 3 months to the number of patients with estimates 3 months apart. Estimated GFR results are flagged by the laboratory as abnormal based on normal age and sex limits and are reported as abnormal to the primary care physician for further assessment of chronic kidney disease. Second, we estimated the rate of primary caregiver recognition/diagnosis of chronic kidney disease as documented in the medical record for patients with chronic kidney disease as defined by the KDOQI guidelines. Sample size calculations for construction of a 95% confidence interval (CI) to estimate diagnostic reporting rates within 10% of the true population rate required that medical records from

Ryan et al Chronic Kidney Disease 983 100 subjects be reviewed. 25 With proportionate sampling by race, we randomly selected 102 patients among the 6895 who met the KDOQI definition of chronic kidney disease. The recognition/diagnosis of chronic kidney disease was defined as any written evidence in each patient s record that the physician had diagnosed chronic kidney disease. A diagnosis was noted if the physician ordered further clinical testing for renal impairment, referred the patient to a kidney specialist, or wrote in the patient record that chronic kidney disease was present. The chart review was conducted in 2005 and included all records from 2003 through May 2005. The initial estimation of GFR in 2003-2004 was determined using enzymatic S cr values and the original MDRD formula: GFR 186 * S cr 1.154 * age 0.203 * 0.742 if female * 1.210 if African-American. These estimated GFR values were reported to the primary physician and used for the selection of chronic kidney disease patients to estimate the rate of diagnosis. 14,24 The estimated GFRs derived from the original formula were compared with those derived using the re-expressed MDRD formula with no change in chronic kidney disease prevalence. Statistical Analysis Descriptive statistics are presented as percentages, or means with standard deviations. A mean GFR for each individual was the basis for calculation of the group mean. Differences between groups for categorical and continuous variables were examined using chi-squared tests or Student s t tests, respectively. Statistical significance was ascribed to 2-sided P values.05. Data were normally distributed; analysis was performed using SAS Windows, version 9.1 (SAS Institute Inc., Cary, NC). RESULTS The initial dataset contained 100,176 unique patients. A total of 9321 patients were excluded due to missing personal identifiers, or demographic information. Additionally, 7879 patients were excluded from the sample due to inpatient status. The final study sample consisted of 82,976 unique patients with 170,581 observations. The cohort demographics were as follows: 56% was female, 82% was Caucasian, mean age was 56.2 17.1 years, and the mean estimated GFR was 77.1 ml/min/1.73 m 2 21.54. Prevalence of Chronic Kidney Disease Among the 82,976 outpatients who had S cr measured, 17,827 had at least one GFR 60 ml/min/1.73 m 2.Ifwe define chronic kidney disease (CKD) as a single GFR 60 ml/min/1.73 m 2, this would indicate a period prevalence of 21.5%. 9-13 However, using the KDOQI guidelines definition as a GFR 60 ml/min/1.73 m 2 for 3 months, we found that the prevalence was higher. Among the 82,976 Table 1 Demographics of Outpatient Population Outpatients Not Meeting KDOQI Definition (n 76,081) Outpatients Meeting KDOQI Definition (n 6895) P Value Age (years) 54.8 16.6 71.4 14.0.001 Race.001 Caucasian 62,320 (91.17) 6039 (8.83) African American 10,294 (93.85) 675 (6.15) Hispanic 2341 (95.43) 112 (4.57) Asian 1074 (94.71) 60 (5.29) Native American 52 (85.25) 9 (14.75) Sex.001 Male 42,395 (91.00) 4190 (9.00) Female 33,686 (92.57) 2705 (7.43) MDRD GFR 80.04 19.8 45.15 12.57.001 KDOQI Kidney Disease Outcomes Quality Initiative; CKD chronic kidney disease; MDRD Modfication of Diet in Renal Disease; GFR glomerular filtration rate. Note: Values expressed as mean standard deviation for age and MDRD estimated GFR. Otherwise values expressed as number and (percent). Differences between groups for categorical and continuous variables were examined using chi-squared tests or Student s t tests, respectively. Statistical significance was ascribed to 2-sided P-values.05. MDRD estimated GFR are measured in ml/min/1.73 m 2. CKD is defined as an estimated GFR 60 ml/min/1.73 m 2 for 3 months. outpatients, 24,492 had at least 2 estimates 3 months apart. Among these, 6895 had at least 2 GFR 60 ml/min/ 1.73 m 2 3 months apart, indicating a 28.2% period prevalence of chronic kidney disease. The age-specific prevalence ranged from a low of 3.7% among those 18-39 years of age to a high of 51% among those 70 years of age. Based on the 24,492 outpatients, the positive predictive value of a single GFR 60 ml/min/1.73 m 2 as indicative of chronic kidney disease appears to be 73%. The demographic characteristics of the outpatient population with and without CKD are outlined in Table 1. The Figure illustrates estimated GFR distribution. The mean estimated GFR was significantly different in those with CKD (45.15 ml/min/1.73 m 2 ) compared with those without chronic kidney disease (80.04 ml/min/1.73 m 2 )(P.001) (Table 1). Age was also significantly different, with a mean age of 71.4 14.0 years among those with CKD compared with 54.8 16.6 years among patients without CKD (P.001). Among those with chronic kidney disease, 79% were 60 years of age. The racial and sex distributions were significantly different (P.001). Caucasians and Native Americans in this sample of health-seeking individuals were disproportionately more likely to have CKD, as were females (9.0%) compared with males (7.4%) (P.001). Diagnosis To assess the rate of chronic kidney disease diagnoses by primary care providers, we conducted thorough chart re-

984 The American Journal of Medicine, Vol 120, No 11, November 2007 Figure Distribution of estimated GFR values. Estimated GFR distribution among those with CKD (n 6895). Estimated GFR grouping based on KDOQI guidelines. The rate within each category is listed above each bar. Patients mean GFR value was used for categorization. views on a random sample of 102 subjects selected from the 6895 subjects identified as having CKD (Table 2). The rate of clinical diagnosis documented in the patient s Table 2 Demographics of Outpatient Sample with CKD Confirmed Diagnosis (n 27) Unconfirmed Diagnosis (n 75) P Value Age (years) 67.70 15.92 70.21 10.83.37 Race.008 Caucasian 15 (55.56) 61 (81.33) African American 12 (44.44) 14 (18.67) Sex.22 Female 16 (59.26) 54 (72.00) Male 11 (40.74) 21 (28.00) Diabetes (diagnosed) 16 (59.26) 22 (29.33).006 Hypertension 25 (92.60) 47 (62.67).003 (diagnosed) CVD (diagnosed) 14 (51.85) 30 (40.00).286 Anemia (diagnosed) 15 (55.56) 17 (22.67).001 MDRD GFR 33.16 16.02 55.15 7.22.001 CKD chronic kidney disease; CVD cardiovascular disease; MDRD Modfication of Diet in Renal Disease; GFR glomerular filtration rate. Note: Values expressed as mean standard deviation for age and MDRD estimated GFR. Otherwise values expressed as number and (percent). Differences between groups for categorical and continuous variables were examined using chi-squared tests or Student s t tests, respectively. Statistical significance was ascribed to 2-sided P-values.05. MDRD estimated GFR is measured in ml/min/1.73 m 2. CKD is defined as an estimated GFR 60 ml/min/1.73 m 2 for 3 months. Anemia is defined as a hemoglobin value 12.0 g/dl. (Diagnosed) indicates a written diagnosis in the patients records. medical record was 26.5% (95% CI, 17.9 to 35.1), suggesting that 74% of patients are undiagnosed. As shown in Table 2, patients with a clinical diagnosis (n 27) had significantly lower GFR (33.16 vs 55.15), and a higher prevalence of anemia (56% vs 23%), hypertension (93% vs 63%), and diabetes (59% vs 29%), compared with those without a clinical diagnosis (n 75). However, the prevalence of cardiovascular disease was not significantly different between the 2 groups (52% vs 40%) (P.286). Table 3 describes the distribution of GFR by diagnosis. DISCUSSION We demonstrate that the prevalence of chronic kidney disease, defined by a GFR 60 ml/min/1.73 m 2 for 3 months, was 28.5% in 24,492 health-seeking subjects having multiple GFR measures available. Consistent with previous reports, our study reveals that the prevalence was higher among women, Caucasians, and the elderly. 8,11 Furthermore, we estimate that 74% of patients with CKD do Table 3 Distribution of GFR Distribution of GFR by Clinical Diagnosis Confirmed Diagnosis (n 27) Unconfirmed Diagnosis (n 75) 1-14 5 (100.00) 0 (0.00) 15-30 10 (83.33) 2 (16.67) 31-45 9 (39.13) 14 (60.87) 46-59 3 (4.84) 59 (95.16) GFR glomerular filtration rate; CKD chronic kidney disease. Note: Values expressed as number and (percent). MDRD estimated GFR are measured in ml/min/1.73 m 2.

Ryan et al Chronic Kidney Disease 985 not have a documented diagnosis in their medical record. Our findings show that prior estimates prevalence, defined as a single GFR 60, were inflated by approximately 27%. We also demonstrate that CKD prevalence among health-seeking individuals is substantially higher than in the general population. 26 This difference has important implications for identification and management of those with CKD. Given that a majority of the estimated 8.3 million individuals with CKD may already be seeking health care for other reasons, an increased awareness among physicians is likely to maximize detection and management. The rate at which primary care physicians recognize chronic kidney disease and diagnose patients as such should shape the development of effective primary care physician education programs. The poor sensitivity of prior screening tools, particularly the use of S cr values as a marker of renal insufficiency, has been implicated in the lack diagnosis. 27,28 For this reason, Strong Health implemented the MDRD equation in an effort to provide physicians with a more accurate measurement of kidney function to improve the identification of individuals with CKD. Prior studies have estimated the rate of diagnosis; however, diagnostic decisions in these studies were based on S cr values. 12,20 The primary care physicians in our study were making diagnostic decisions based upon estimated GFR. Despite the increased sensitivity of this method, physicians in our study were not likely to document a diagnosis of CKD, as only 26.5% of patients with chronic kidney disease had documentation in their medical record. The data also indicate a possible sex bias in recognition ; evidence of clinical diagnosis was found in only 22.8% of medical records of women, compared with 34.4% of these for men (Table 2). Our findings suggest that physicians are more likely to make the diagnosis as severity of disease increases, with early stages going undiagnosed. Akbari et al found in a limited setting that the use of estimated GFR combined with an educational intervention of physicians significantly improved the rate diagnosis in Canada. 29 The rate of diagnosis increased 3-fold (22.4% to 85.1%) following the implementation of the educational program. It was hypothesized that the implementation of widespread reporting of laboratory GFR without the educational component would increase nephrology referrals and overwhelm specialists. Our findings indicate that, given the low rate of physician-documented diagnosis, the widespread reporting of laboratory GFR alone is unlikely to result in an increase in nephrology referrals. We are not aware of any such change in these referral trends. The underdiagnosis is particularly worrisome given that early identification provides an opportunity to slow the progression and alter the course of disease. Several studies indicate that patients are referred to specialized nephrology care just before the need for dialysis, which is often too late. 28,30,31 Our findings suggest that referrals during late stages may be a result of delay in the early clinical diagnosis by primary care physicians. We speculate that education of primary care physicians on CKD and increased awareness of risk factors may improve the diagnosis rate. The lack of data on microalbuminuria is a limitation of our study. The number of individuals with a GFR 60 and microalbuminuria is unknown. As a consequence, we have underestimated the prevalence among those patients with a GFR 60. Additionally, given that our study includes only individuals seeking health care during the study period, we do not have renal function estimates for the entire catchment population. However, the size and demographic characteristics of our study cohort, and the fact that specimens were collected from primary care offices throughout the County, increase the likelihood of a representative sample. By limiting our study to outpatient S cr values and the use of one laboratory for estimation of GFR, we increased our confidence in the validity of the estimated GFR values. It is very important to note that the prevalence was determined using individuals with 2 observations 90 days apart. It is possible that patients with 2 estimates had more medical problems, particularly hypertension and diabetes, resulting in a slightly inflated prevalence. Additionally, the patients without S cr measurements were likely healthier than those with measured values, and had a lower prevalence than the 28.2% of patients who had 2 or more S cr values. Finally, although the number of chart reviews was limited, our findings indicate that, at best, the rate diagnosis was 35.1%, which indicates a need for improvement. In conclusion, we demonstrate that the prevalence of chronic kidney disease is substantially higher in the healthseeking population based on the National Kidney Foundation clinical definition. The notable difference in the prevalence between health-seeking individuals and the general population has important implications for identification and management of individuals with chronic kidney disease. Moreover, we demonstrate that laboratory reporting of estimated GFR using the MDRD equation alone does not result in an optimal rate of clinical diagnosis, with 74% of patients remaining undiagnosed. ACKNOWLEDGMENTS We thank Dr. Elizabeth Ryan for insightful comments on this manuscript. This study was supported in part by National Heart, Lung, and Blood Institute T32 HL-07937 and Amgen, Thousand Oaks, California. References 1. U.S. Department of Health and Human Services. Healthy People 2010: Understanding and Improving Health, 2nd edition. Washington, DC: U.S. Government Printing Office; 2000. 2. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1-S266.

986 The American Journal of Medicine, Vol 120, No 11, November 2007 3. Chronic kidney disease: stating the managed care case for early treatment. Discussion and consensus of presentations of economic analyses, managed care organization case studies, and opportunities for intervention in a managed care setting. May 3-5, 2001 Chicago, Illinois. Am J Manag Care. 2002;8(4 Suppl):S114-S120. 4. National Kidney Disease Education Program Baseline Report. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health; 2001. 5. Eknoyan G, Levey AS, Levin NW, Keane WF. The national epidemic of chronic kidney disease. What we know and what we can do. Postgrad Med. 2001;110(3):23-29: quiz 8. 6. Parmar MS. Chronic renal disease. BMJ. 2002;325(7355):85-90. 7. St Peter WL, Schoolwerth AC, McGowan T, McClellan WM. Chronic kidney disease: issues and establishing programs and clinics for improved patient outcomes. Am J Kidney Dis. 2003;41(5):903-924. 8. Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41(1):1-12. 9. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351(13):1285-1295. 10. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296-1305. 11. Keith DS, Nichols GA, Gullion CM, et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164(6):659-663. 12. Stevens LA, Fares G, Fleming J, et al. Low rates of testing and diagnostic codes usage in a commercial clinical laboratory: evidence for lack of physician awareness of chronic kidney disease. JAmSoc Nephrol. 2005;16(8):2439-2448. 13. Anandarajah S, Tai T, de Lusignan S, et al. The validity of searching routinely collected general practice computer data to identify patients with chronic kidney disease (CKD): a manual review of 500 medical records. Nephrol Dial Transplant. 2005;20(10):2089-2096. 14. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461-470. 15. Lewis J, Agodoa L, Cheek D, et al. Comparison of cross-sectional renal function measurements in African Americans with hypertensive nephrosclerosis and of primary formulas to estimate glomerular filtration rate. Am J Kidney Dis. 2001;38(4):744-753. 16. Kuan Y, Hossain M, Surman J, et al. GFR prediction using the MDRD and Cockcroft and Gault equations in patients with end-stage renal disease. Nephrol Dial Transplant. 2005;20(11):2394-2401. 17. Poggio ED, Wang X, Greene T, et al. Performance of the modification of diet in renal disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease. J Am Soc Nephrol. 2005;16(2):459-466. 18. Rule AD, Larson TS, Bergstralh EJ, et al. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med. 2004;141(12):929-937. 19. Fontsere N, Bonal J, Navarro M, et al. A comparison of prediction equations for estimating glomerular filtration rate in adult patients with chronic kidney disease stages 4-5. Effect of nutritional status and age. Nephron Clin Pract. 2006;104(4):c160-c168. 20. Coresh J, Byrd-Holt D, Astor BC, et al. Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. J Am Soc Nephrol. 2005;16(1):180-188. 21. New York State Department of Health. New York State Vital Statistics: 2002 Annual Report. Albany, NY: NYS Health Department. 22. United States Census Bureau. 2004 American Community Survey. Washington, DC: US Census Bureau. 23. Myers GL, Miller WG, Coresh J, et al. Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin Chem. 2006;52:1-18. 24. Levey A, Coresh J, Greene T, et al. Expressing the MDRD study equation for estimating GFR with IDMS traceable (gold standard) serum creatinine values. J Am Soc Nephrol. 2005;16:69A. 25. Hennekens C, Buring JE. Epidemiology in Medicine. Boston, MA: Little, Brown and Company; 1987. 26. Clase CM, Garg AX, Kiberd BA. Prevalence of low glomerular filtration rate in nondiabetic Americans: Third National Health and Nutrition Examination Survey (NHANES III). J Am Soc Nephrol. 2002;13(5):1338-1349. 27. Swedko PJ, Clark HD, Paramsothy K, Akbari A. Serum creatinine is an inadequate screening test for renal failure in elderly patients. Arch Intern Med. 2003;163(3):356-360. 28. Mendelssohn DC, Kua BT, Singer PA. Referral for dialysis in Ontario. Arch Intern Med. 1995;155(22):2473-2478. 29. Akbari A, Swedko PJ, Clark HD, et al. Detection of chronic kidney disease with laboratory reporting of estimated glomerular filtration rate and an educational program. Arch Intern Med. 2004;164(16): 1788-1792. 30. Nissenson AR, Collins AJ, Hurley J, et al. Opportunities for improving the care of patients with chronic renal insufficiency: current practice patterns. J Am Soc Nephrol. 2001;12(8):1713-1720. 31. Cass A, Cunningham J, Snelling P, Ayanian JZ. Late referral to a nephrologist reduces access to renal transplantation. Am J Kidney Dis. 2003;42(5):1043-1049.